<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886973</url>
  </required_header>
  <id_info>
    <org_study_id>FNU-3549-20-23-1</org_study_id>
    <nct_id>NCT04886973</nct_id>
  </id_info>
  <brief_title>Effect of Insulin Resistance on Branched Chain Amino Acid Metabolism.</brief_title>
  <acronym>BCAA</acronym>
  <official_title>Effect of Insulin Resistance on Branched Chain Amino Acid Metabolism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been observed that subjects with obesity and insulin resistance have higher&#xD;
      concentrations of branched chain amino acids in plasma or serum. However, this association&#xD;
      has been established under fasting conditions, so they only give information about a&#xD;
      metabolic state and do not reflect the dynamics and flexibility of the metabolism of these&#xD;
      amino acids in the absence or presence of insulin resistance. The main aim of this study is&#xD;
      to compare the catabolism of branched chain amino acids and their keto acids in subjects with&#xD;
      and without insulin resistance, after the infusion of an amino acid solution with high&#xD;
      concentration of the branched chain amino acids, leucine, valine, and isoleucine. The results&#xD;
      of this project will allow the investigators to understand the dynamics of the branched chain&#xD;
      amino acids and their derivatives, and its relationship with insulin resistance, which could&#xD;
      eventually be used to design nutritional strategies to treat insulin resistance and thus,&#xD;
      delay the development of type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An 8% crystalline L-amino acid solution with high concentrations of branched chain amino&#xD;
      acids, leucine, isoleucine, and valine, will be administered intravenously. The dose will be&#xD;
      calculated considering the 25% of the estimated protein per day. For example, if the patient&#xD;
      is 70 kg and the investigators consider 1g/kg/day, the amount of protein to be administered&#xD;
      will be 17.5 grams (70 x 0.25 = 17.5 grams). This dose will be placed in a short peripheral&#xD;
      intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump.&#xD;
      The patient will be monitored all the time by a physician. After the administration of the L-&#xD;
      amino acid solution, the investigators will take blood samples at 0, 15, 30, 45, 60, 90 and&#xD;
      120 minutes to determine the area under the curve for glucose, insulin, amino acids and&#xD;
      branched chain keto acids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The groups will receive the treatment simultaneously</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of branched-chain amino acids.</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0,15,30,45,60,90,120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The branched chain amino acids concentration will be determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS), and the area under the curve will be calculated using the trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of branched-chain keto acids.</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0,15,30,45,60,90,120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The branched chain keto acids concentration will be determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS), and the area under the curve will be calculated using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of insulin.</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0,15,30,45,60,90,120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The insulin concentration will be determined using an ELISA assay and the area under the curve will be calculated using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of glucose.</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0,15,30,45,60,90,120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The glucose concentration will be determined using an enzymatic assay (Hexokinase) and the area under the curve will be calculated using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory quotient.</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0,15,30,45,60,90,120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids The respiratory quotient will be determined by indirect calorimetry and the area under the curve will be calculated using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the enzyme branched-chain aminotransferase 2 (BCAT2)</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0, 60 and 120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The expression of enzyme branched chain aminotransferase 2 (BCAT2) will be determined in mononuclear cells isolated from blood by Western Blot and quantitative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of the enzyme branched-chain keto acid dehydrogenase (BCKDH)</measure>
    <time_frame>2 hours</time_frame>
    <description>Time Frame: Measured for 0, 60 and 120 minutes following the intravenous administration of the amino acid solution rich in branched chain amino acids.&#xD;
The expression of enzyme branched chain ketoacid dehydrogenase (BCKDH) will be determined in mononuclear cells isolated from blood by Western Blot and quantitative PCR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) &lt; 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.</intervention_name>
    <description>Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.</description>
    <arm_group_label>Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) &lt; 2.5</arm_group_label>
    <arm_group_label>Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for cases (subjects with insulin resistance).&#xD;
&#xD;
          -  Male and female.&#xD;
&#xD;
          -  Adults between 18 and 50 years of age.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 40 kg/m2.&#xD;
&#xD;
          -  HOMA index ≥ 2.5&#xD;
&#xD;
          -  In the case of women, being in the follicular phase of the menstrual cycle.&#xD;
&#xD;
        Inclusion criteria for controls (subjects without insulin resistance).&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Adults between 18 and 50 years of age.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 40 kg/m2.&#xD;
&#xD;
          -  HOMA index &lt; 2.5&#xD;
&#xD;
          -  Blood glucose &lt; 100 mg/dL&#xD;
&#xD;
          -  In the case of women, being in the follicular phase of the menstrual cycle.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any type of diabetes.&#xD;
&#xD;
          -  Patients with kidney disease diagnosed by any physician.&#xD;
&#xD;
          -  Patients with creatinine &gt; 1.3 mg/dL for men and &gt; 1.1 mg/dL for women and/or Blood&#xD;
             Urea Nitrogen (BUN) &gt; 20 mg/dL.&#xD;
&#xD;
          -  Patients with acquired diseases secondarily producing obesity and diabetes.&#xD;
&#xD;
          -  Patients who have suffered a cardiovascular event.&#xD;
&#xD;
          -  Weight loss &gt; 3 kg in the last 3 months.&#xD;
&#xD;
          -  Patients with any catabolic diseases.&#xD;
&#xD;
          -  Pregnancy status.&#xD;
&#xD;
          -  Positive smoking.&#xD;
&#xD;
          -  Treatment with any medication (except contraceptives and proton pump inhibitors)&#xD;
&#xD;
          -  Having suffered any infection in the last 20 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIA VIRIDIANA OLIN SANDOVAL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARIA VIRIDIANA OLIN-SANDOVAL, Dr</last_name>
    <phone>5554870900</phone>
    <phone_ext>2802</phone_ext>
    <email>viridiana.olins@incmnsz.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARTHA GUEVARA-CRUZ, Dr</last_name>
    <phone>5554870900</phone>
    <phone_ext>2802</phone_ext>
    <email>martha.guevarac@incmnsz.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>MARIA VIRIDIANA OLIN-SANDOVAL, Dr</last_name>
      <phone>5554870900</phone>
      <phone_ext>2802</phone_ext>
      <email>viridiana.olins@incmnsz.mx</email>
    </contact>
    <contact_backup>
      <last_name>MARTHA GUEVARA-CRUZ, Dr</last_name>
      <phone>5554870900</phone>
      <phone_ext>2802</phone_ext>
      <email>martha.guevarac@incmnsz.mx</email>
    </contact_backup>
    <investigator>
      <last_name>MARIA VIRIDIANA OLIN-SANDOVAL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARTHA GUEVARA-CRUZ, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Shimomura Y, Yamamoto Y, Bajotto G, Sato J, Murakami T, Shimomura N, Kobayashi H, Mawatari K. Nutraceutical effects of branched-chain amino acids on skeletal muscle. J Nutr. 2006 Feb;136(2):529S-532S.</citation>
    <PMID>16424141</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Zeng X, Ren M, Mao X, Qiao S. Novel metabolic and physiological functions of branched chain amino acids: a review. J Anim Sci Biotechnol. 2017 Jan 23;8:10. doi: 10.1186/s40104-016-0139-z. eCollection 2017. Review.</citation>
    <PMID>28127425</PMID>
  </reference>
  <reference>
    <citation>Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr. 2006 Jan;136(1 Suppl):207S-11S. doi: 10.1093/jn/136.1.207S. Review.</citation>
    <PMID>16365084</PMID>
  </reference>
  <reference>
    <citation>Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009 Apr;9(4):311-26. doi: 10.1016/j.cmet.2009.02.002. Erratum in: Cell Metab. 2009 Jun;9(6):565-6.</citation>
    <PMID>19356713</PMID>
  </reference>
  <reference>
    <citation>Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost HG, Fritsche A, Häring HU, Hrabě de Angelis M, Peters A, Roden M, Prehn C, Wang-Sattler R, Illig T, Schulze MB, Adamski J, Boeing H, Pischon T. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013 Feb;62(2):639-48. doi: 10.2337/db12-0495. Epub 2012 Oct 4.</citation>
    <PMID>23043162</PMID>
  </reference>
  <reference>
    <citation>Zhao X, Han Q, Liu Y, Sun C, Gang X, Wang G. The Relationship between Branched-Chain Amino Acid Related Metabolomic Signature and Insulin Resistance: A Systematic Review. J Diabetes Res. 2016;2016:2794591. doi: 10.1155/2016/2794591. Epub 2016 Aug 25. Review.</citation>
    <PMID>27642608</PMID>
  </reference>
  <reference>
    <citation>Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011 Apr;17(4):448-53. doi: 10.1038/nm.2307. Epub 2011 Mar 20.</citation>
    <PMID>21423183</PMID>
  </reference>
  <reference>
    <citation>Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014 Dec;10(12):723-36. doi: 10.1038/nrendo.2014.171. Epub 2014 Oct 7. Review.</citation>
    <PMID>25287287</PMID>
  </reference>
  <reference>
    <citation>Serralde-Zúñiga AE, Guevara-Cruz M, Tovar AR, Herrera-Hernández MF, Noriega LG, Granados O, Torres N. Omental adipose tissue gene expression, gene variants, branched-chain amino acids, and their relationship with metabolic syndrome and insulin resistance in humans. Genes Nutr. 2014 Nov;9(6):431. doi: 10.1007/s12263-014-0431-5. Epub 2014 Sep 27.</citation>
    <PMID>25260659</PMID>
  </reference>
  <reference>
    <citation>Gunnerud U, Holst JJ, Östman E, Björck I. The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot- study of bovine and human milk. Nutr J. 2012 Oct 12;11:83. doi: 10.1186/1475-2891-11-83.</citation>
    <PMID>23057765</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Maria Viridiana Olin Sandoval</investigator_full_name>
    <investigator_title>Medical Sciences Investigator C</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

